Express Scripts

A report from the  Institute for Clinical and Economic Review, a nonprofit organization that last year  warned about the costs of new drugs to treat hepatitis C, now says two new drugs — Rapatha, from Amgen, and Praluent, from Sanofi and Regeneron Pharmaceuticals — are vastly overpriced when considering the health outcomes they provide.

The analysis said that, measured by the health benefits, their price should be only a third of the level set  by the makers. The report will increase pressure on the drug companies from providers to cut their prices. Meanwhile, Express Scripts, the largest pharmaceutical benefits manager, plans to use the report’s findings in negotiating with these drug companies.